Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Capital Expenditures (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Capital Expenditures for 8 consecutive years, with $1.7 million as the latest value for Q1 2026.

  • Quarterly Capital Expenditures rose 42.22% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Feb 2026, up 32337.78% year-over-year, with the annual reading at $14.0 million for FY2025, 752.22% up from the prior year.
  • Capital Expenditures for Q1 2026 was $1.7 million at Nurix Therapeutics, down from $11.9 million in the prior quarter.
  • The five-year high for Capital Expenditures was $11.9 million in Q4 2025, with the low at -$8.3 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $1.6 million, with a median of $1.7 million recorded in 2026.
  • Peak annual rise in Capital Expenditures hit 1817.8% in 2022, while the deepest fall reached 262.07% in 2022.
  • Over 5 years, Capital Expenditures stood at -$8.3 million in 2022, then surged by 188.45% to $7.3 million in 2023, then tumbled by 175.2% to -$5.5 million in 2024, then skyrocketed by 315.06% to $11.9 million in 2025, then tumbled by 85.68% to $1.7 million in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.7 million, $11.9 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.